2024-12-01 2025-11-30 2025-11-30 false 08021238 MEDIC4 Limited 86900Other human health activities iso4217:GBP xbrli:pure 080212382024-12-01 080212382025-11-30 080212382024-12-01 2025-11-30 08021238bus:SmallEntities2024-12-01 2025-11-30 08021238bus:AuditExempt-NoAccountantsReport2024-12-01 2025-11-30 08021238bus:FullAccounts2024-12-01 2025-11-30 08021238core:WithinOneYear2025-11-30 08021238core:AfterOneYear2025-11-30 08021238core:WithinOneYear2024-12-01 2025-11-30 08021238core:AfterOneYear2024-12-01 2025-11-30 08021238core:CurrentFinancialInstruments2025-11-30 08021238core:Non-currentFinancialInstruments2025-11-30 08021238core:CurrentFinancialInstruments2024-12-01 2025-11-30 08021238core:Non-currentFinancialInstruments2024-12-01 2025-11-30 08021238core:LandBuildings2024-12-01 2025-11-30 08021238core:FurnitureFittings2024-12-01 2025-11-30 08021238core:OfficeEquipment2024-12-01 2025-11-30 08021238core:Vehicles2024-12-01 2025-11-30 08021238core:PlantMachinery2024-12-01 2025-11-30 08021238core:OtherPropertyPlantEquipment2024-12-01 2025-11-30 08021238core:LandBuildings2025-11-30 08021238core:PlantMachinery2025-11-30 08021238core:Vehicles2025-11-30 08021238core:FurnitureFittings2025-11-30 08021238core:OfficeEquipment2025-11-30 08021238core:OtherPropertyPlantEquipment2025-11-30 08021238core:Right-of-useAssets2024-12-01 2025-11-30 08021238core:Right-of-useAssets2025-11-30 08021238core:Goodwill2024-12-01 2025-11-30 08021238core:PatentsTrademarksLicencesConcessionsSimilar2024-12-01 2025-11-30 08021238core:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-12-01 2025-11-30 08021238core:OtherResidualIntangibleAssets2024-12-01 2025-11-30 08021238core:Goodwill2025-11-30 08021238core:DevelopmentCostsCapitalisedDevelopmentExpenditure2025-11-30 08021238core:PatentsTrademarksLicencesConcessionsSimilar2025-11-30 08021238core:OtherResidualIntangibleAssets2025-11-30 08021238dpl:CostSales2024-12-01 2025-11-30 08021238dpl:AdministrativeExpenses2024-12-01 2025-11-30 08021238dpl:DistributionCosts2024-12-01 2025-11-3008021238core:ShareCapital2025-11-30 08021238core:SharePremium2025-11-30 08021238core:RevaluationReserve2025-11-30 08021238core:OtherReservesSubtotal2025-11-30 08021238core:ShareCapitalPreferenceShares2025-11-30 08021238core:CapitalRedemptionReserve2025-11-30 08021238core:OtherCapitalReserve2025-11-30 08021238core:RetainedEarningsAccumulatedLosses2025-11-3008021238core:ShareCapital2024-12-01 2025-11-30 08021238core:SharePremium2024-12-01 2025-11-30 08021238core:RevaluationReserve2024-12-01 2025-11-30 08021238core:OtherReservesSubtotal2024-12-01 2025-11-30 08021238core:RetainedEarningsAccumulatedLosses2024-12-01 2025-11-300802123812024-12-01 2025-11-30 0802123822024-12-01 2025-11-3008021238core:ShareCapital12024-12-01 2025-11-30 08021238core:ShareCapital22024-12-01 2025-11-3008021238core:SharePremium12024-12-01 2025-11-30 08021238core:SharePremium22024-12-01 2025-11-3008021238core:RevaluationReserve12024-12-01 2025-11-30 08021238core:RevaluationReserve22024-12-01 2025-11-3008021238core:RetainedEarningsAccumulatedLosses12024-12-01 2025-11-30 08021238core:RetainedEarningsAccumulatedLosses22024-12-01 2025-11-300802123812024-12-01 2025-11-3008021238core:Non-currentFinancialInstrumentscore:CostValuation2024-12-01 08021238core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-11-30 08021238core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-11-30 08021238core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-11-30 08021238core:Non-currentFinancialInstrumentscore:TransfersIntoOrOutInvestmentsIncreaseDecreaseInInvestments2025-11-30 08021238core:Non-currentFinancialInstrumentscore:CostValuation2025-11-3008021238core:Non-currentFinancialInstrumentscore:ProvisionsForImpairmentInvestments2024-12-01 08021238core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-11-30 08021238core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-11-30 08021238core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-11-30 08021238core:Non-currentFinancialInstrumentscore:FurtherSpecificIncreaseDecreaseInProvisionsForImpairmentInvestments1ComponentCorrespondingTotal2025-11-30 08021238core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-11-30 08021238core:Non-currentFinancialInstrumentscore:ProvisionsForImpairmentInvestments2025-11-3008021238core:Non-currentFinancialInstruments2025-11-30 08021238core:Non-currentFinancialInstruments2024-11-30080212382023-12-01 080212382024-11-30 080212382023-12-01 2024-11-30 08021238core:WithinOneYear2024-11-30 08021238core:AfterOneYear2024-11-30 08021238core:CurrentFinancialInstruments2024-11-30 08021238core:Non-currentFinancialInstruments2024-11-30 08021238core:LandBuildings2024-11-30 08021238core:PlantMachinery2024-11-30 08021238core:Vehicles2024-11-30 08021238core:FurnitureFittings2024-11-30 08021238core:OfficeEquipment2024-11-30 08021238core:OtherPropertyPlantEquipment2024-11-30 08021238core:Right-of-useAssets2024-11-30 08021238core:Goodwill2024-11-30 08021238core:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-11-30 08021238core:PatentsTrademarksLicencesConcessionsSimilar2024-11-30 08021238core:OtherResidualIntangibleAssets2024-11-30 08021238dpl:AdministrativeExpenses2023-12-01 2024-11-3008021238core:ShareCapital2024-11-30 08021238core:SharePremium2024-11-30 08021238core:RevaluationReserve2024-11-30 08021238core:OtherReservesSubtotal2024-11-30 08021238core:ShareCapitalPreferenceShares2024-11-30 08021238core:CapitalRedemptionReserve2024-11-30 08021238core:OtherCapitalReserve2024-11-30 08021238core:RetainedEarningsAccumulatedLosses2024-11-3008021238core:RetainedEarningsAccumulatedLosses2023-12-01 08021238core:ShareCapital2023-12-01 08021238core:SharePremium2023-12-01 08021238core:RevaluationReserve2023-12-01 08021238core:ShareCapital2023-12-01 2024-11-30 08021238core:SharePremium2023-12-01 2024-11-30 08021238core:RevaluationReserve2023-12-01 2024-11-30 08021238core:OtherReservesSubtotal2023-12-01 2024-11-30 08021238core:RetainedEarningsAccumulatedLosses2023-12-01 2024-11-300802123812023-12-01 2024-11-30 0802123822023-12-01 2024-11-3008021238core:ShareCapital12023-12-01 2024-11-30 08021238core:ShareCapital22023-12-01 2024-11-3008021238core:SharePremium12023-12-01 2024-11-30 08021238core:SharePremium22023-12-01 2024-11-3008021238core:RevaluationReserve12023-12-01 2024-11-30 08021238core:RevaluationReserve22023-12-01 2024-11-3008021238core:RetainedEarningsAccumulatedLosses12023-12-01 2024-11-30 08021238core:RetainedEarningsAccumulatedLosses22023-12-01 2024-11-3008021238bus:Director12024-12-01 2025-11-3008021238bus:PrivateLimitedCompanyLtd2024-12-01 2025-11-30
MEDIC4 Limited
Unaudited Financial Statements
for the year ended 30 November 2025
Company registration number 08021238
(England and Wales)

Company Information

For the year ended 30 November 2025
Director Dr H C Romer

Registered office 40 Hoghton Street
Southport
PR9 0PQ

Registered number 08021238

Accountant J A Fell & Co
40 Hoghton Street
Southport
England
PR9 0PQ

Statement of Financial Position

As at 30 November 2025
Notes
2025
2024
£
£
£
£
Fixed assets
Tangible assets
4
13,801
-
Investments
610,313
540,951
624,114
540,951
Current assets
Debtors
5
194,495
205,535
Cash at bank and in hand
93,294
56,118
287,789
261,653
Creditors
Amounts falling due within one year
6
(74,332)
(42,300)
(74,332)
(42,300)
Net current assets (liabilities)
213,457
219,353
Total assets less current liabilities
837,571
760,304
Net assets (liabilities)
837,571
760,304
Capital and reserves
Called up share capital
100
100
Profit and loss account
837,471
760,204
Total equity
837,571
760,304

The company is a private company limited by shares and registered in England and Wales. It was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.
The financial statements have been prepared in accordance with the special provisions applicable to companies subject to the small companies regime.
The directors have chosen to not file a copy of the company's profit and loss account under section 444 (5A) of the Companies Act 2006.

The financial statements were approved and authorised for issue by the director on 28 August 2026 and are signed on its behalf by:

Dr H C Romer
Dr H C Romer
Director

Company registration number 08021238

Notes to the Financial Statements

For the year ended 30 November 2025

1. Statutory information

The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The financial statements are presented in sterling and this is the functional currency of the company.

2. Accounting policies

2.1. Basis of preparation

The financial statements have been prepared in accordance with FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.

The financial statements have been prepared under the historical cost convention in accordance with the Companies Act 2006.

2.2. Turnover

Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services.

2.3. Pensions

Defined contribution pension plan

The company operates a defined contribution pension plan for the benefit of its employees. Contributions are recognised as expenses as they become payable. Differences between contributions payable in the year and those actually paid are recognised as either prepayments or accruals in the balance sheet. The assets of the defined contribution pension scheme are held separately from those of the company in an independently administered fund.

2.4. Interest receivable

Interest income is recognised using the effective interest rate method.

2.5. Tangible fixed assets and depreciation

All fixed assets are initially recorded at cost. Property, plant and equipment is used in the company's principal activity for the production and supply of goods or for administrative purposes and is stated in the balance sheet under the historic cost model. This model requires the assets to be stated at cost less amounts in respect of depreciation and less any accumulated impairment losses. Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value (which is the expected amount that would currently be obtained from disposal of an asset, after deducting the estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life), over the useful economic life of the respective asset as follows:

Rate
Method
%
Plant and machinery
25
Straight-line
Office and computer equipment
25
Straight-line

2.6. Financial instruments

Election and recognition

The company has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.


Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument. Financial assets and liabilities are offset with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Other financial assets

Other financial assets, including investments in equity instruments which are not subsidiaries, associates or joint ventures, are initially measured at fair value, which is normally the transaction price. Such assets are subsequently carried at fair value and the changes in fair value are recognised in profit or loss, except that investments in equity instruments that are not publicly traded and whose fair values cannot be measured reliably are measured at cost less impairment.

Impairment of financial assets

Financial assets, other than those held at fair value through profit and loss, are assessed for indicators of impairment at each reporting end date.


Financial assets are impaired where there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows have been affected. If an asset is impaired, the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset's original effective interest rate. The impairment loss is recognised in profit or loss.


If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been, had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.

Derecognition of financial assets

Financial assets are derecognised only when the contractual rights to the cash flows from the asset expire or are settled, or when the company transfers the financial asset and substantially all the risks and rewards of ownership to another entity, or if some significant risks and rewards of ownership are retained but control of the asset has transferred to another party that is able to sell the asset in its entirety to an unrelated third party.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.


Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.


Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the company's contractual obligations expire or are discharged or cancelled.

2.7. Trade and other debtors

Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.

3. Employees

The average number of employees during the year was 1 (2024: 1).

4. Tangible fixed assets

Plant and machinery
Office equipment
Total
£
£
£
Cost
At 1 December 2024
17,846
1,064
18,910
Additions
18,274
-
18,274
At 30 November 2025
36,120
1,064
37,184
Depreciation and impairment
At 1 December 2024
17,846
1,064
18,910
Charge for the period
4,473
-
4,473
At 30 November 2025
22,319
1,064
23,383
Net book value
At 30 November 2025
13,801
-
13,801
At 30 November 2024
-
-
-

5. Debtors

2025
2024
£
£
Trade debtors
44,495
55,535
Total due within one year
44,495
55,535
Other debtors
150,000
150,000
Total due after one year
150,000
150,000
Total
194,495
205,535

6. Creditors due within one year

2025
2024
£
£
Other creditors
62,966
38,541
Taxation and social security
8,966
259
Accruals and deferred income
2,400
3,500
Total
74,332
42,300